Last reviewed · How we verify
Bactocill In Plastic Container (OXACILLIN)
Bactocill In Plastic Container (Oxacillin) is a penicillin-class antibacterial medication originally developed by Sandoz and currently owned by Apothecon. It targets prostaglandin G/H synthase 1 and is used to treat various bacterial infections, including those caused by Staphylococcus aureus. The medication is available as a generic product, with 15 manufacturers, and is off-patent. Key safety considerations include its short half-life of 0.7 hours and limited bioavailability of 33%. It is FDA-approved for several indications, including acute bacterial sinusitis and osteomyelitis.
At a glance
| Generic name | OXACILLIN |
|---|---|
| Sponsor | Apothecon |
| Target | Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Acute bacterial sinusitis
- Continuation Therapy for Acute Osteomyelitis
- Continuation Therapy for Chronic Osteomyelitis
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Lower respiratory tract infection
- Osteomyelitis due to Staphylococcus aureus
- Pharyngitis
- Sepsis due to Staphylococcus aureus
- Sinusitis
- Staphylococcal Prosthetic Heart Valve Endocarditis
- Staphylococcal endocarditis
- Staphylococcal infectious disease
- Staphylococcal meningitis
- Staphylococcal pneumonia
- Staphylococcal septicemia
- Staphylococcus Aureus Bronchitis
- Staphylococcus Aureus Joint Infection
- Staphylococcus Aureus Urinary Tract Infection
Common side effects
- Allergic reactions
- Urticaria
- Pruritus
- Angioneurotic edema
- Laryngospasm
- Bronchospasm
- Hypotension
- Vascular collapse
- Death
- Serum sickness-like symptoms
- Fever
- Malaise
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia (NA)
- Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Oral-only Antibiotics for Bone and Joint Infections in Children (PHASE4)
- Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bactocill In Plastic Container CI brief — competitive landscape report
- Bactocill In Plastic Container updates RSS · CI watch RSS